The FDA issued a final rule clarifying how nonanimal testing methods can be used in preclinical development when appropriate for assessing safety of drugs and biologics for human use. The agency framed the rule as another step away from mandatory animal testing requirements. Regulated firms may use the update to better plan preclinical safety packages and justify alternative methods in submissions. The rule’s practical impact will depend on how it integrates with existing guidance and review expectations across therapeutic areas.